Hansa Biopharma — Januar 2024
-
Hansa Biopharma preliminary Q4: Imlifidase records a very healthy improvement during Q4 after a quarter with low activity
-
Sarepta Therapeutics lukkede oppe +16% i går i US.
"FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy"
FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy
At an event on the sidelines of the J.P. Morgan Healthcare Conference, Marks seemed comfortable with granting some form of full approval to Elevidys.
STAT (www.statnews.com)
Selvom "virker tilbøjelig" ikke bekræfter direkte, så antyder det ... så måske positiv afsmitning på Hansa Biopharma i et ellers nok rødt marked i dag onsdag.
-
Kort video...Hansa Biopharma, som har været et smertens barn, er kommet i gang med salget af et stof til nyretransplantation, og det har markedet taget godt imod.
https://www.proinvestor.com/boards/117934 -
Investorerne er afventende. Hansa brænder kontanter af hver dag. Mit bud er at der kommer en kapitaludvidelse indenfor 0-6 måneder, og at det kommer til at ligge i størrelseorden 5-800 mio. SEK. Nok til at dække min. 1 års forbrug. Kapitaludvidelser er bare gift for biotek for øjeblikket. Især i selskaber hvor der ikke er tillid og fremdrift. Seneste eksempel på hvor dårligt det kan times er Xbrane, uden sammenligning i øvrigt. Jeg kigger tidligst på HANSA igen ifb med en kapitaludvidelse.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind